- Home
- GTX vs MYGN Comparison
GTX vs MYGN Comparison
Compare GTX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTX
- MYGN
- Stock Information
- Founded
- GTX 2018
- MYGN 1991
- Country
- GTX Switzerland
- MYGN United States
- Employees
- GTX N/A
- MYGN N/A
- Industry
- GTX Auto Parts:O.E.M.
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GTX Consumer Discretionary
- MYGN Health Care
- Exchange
- GTX Nasdaq
- MYGN Nasdaq
- Market Cap
- GTX 1.8B
- MYGN 2.0B
- IPO Year
- GTX N/A
- MYGN 1995
- Fundamental
- Price
- GTX $9.60
- MYGN $12.57
- Analyst Decision
- GTX Strong Buy
- MYGN Hold
- Analyst Count
- GTX 1
- MYGN 12
- Target Price
- GTX $12.00
- MYGN $23.92
- AVG Volume (30 Days)
- GTX 853.2K
- MYGN 1.0M
- Earning Date
- GTX 02-13-2025
- MYGN 02-25-2025
- Dividend Yield
- GTX 2.51%
- MYGN N/A
- EPS Growth
- GTX N/A
- MYGN N/A
- EPS
- GTX 1.01
- MYGN N/A
- Revenue
- GTX $3,576,000,000.00
- MYGN $823,600,000.00
- Revenue This Year
- GTX N/A
- MYGN $13.73
- Revenue Next Year
- GTX $3.10
- MYGN $4.34
- P/E Ratio
- GTX $9.46
- MYGN N/A
- Revenue Growth
- GTX N/A
- MYGN 12.15
- 52 Week Low
- GTX $7.13
- MYGN $12.17
- 52 Week High
- GTX $10.16
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- GTX 63.45
- MYGN 32.55
- Support Level
- GTX $8.71
- MYGN $12.17
- Resistance Level
- GTX $9.51
- MYGN $15.08
- Average True Range (ATR)
- GTX 0.24
- MYGN 0.80
- MACD
- GTX 0.01
- MYGN -0.03
- Stochastic Oscillator
- GTX 89.16
- MYGN 13.75
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.